Nutrition Care Strategies at the Intersection of Menopause and Obesity Pharmacotherapy.
Key claim: Incretin mimetic pharmacotherapies cause appetite suppression and reduced dietary intake that compound menopausal estrogen decline, accelerating risks of sarcopenic obesity and osteoporosis unless mitigated by protein optimization and targeted clinical strategies.
Abstract
The premenopause to menopause transition, known as perimenopause, is a critical period of metabolic vulnerability, characterized by hormonal changes, shifts in body composition, and increased cardiometabolic risk. Concurrently, incretin mimetic pharmacotherapies have emerged as highly effective treatments for obesity, achieving weight reductions that are approximating those previously observed only after bariatric surgery. While these agents confer substantial benefits, their mechanisms-appetite suppression, delayed gastric emptying, and enhanced satiety-introduce nutritional risks that intersect with pre-existing vulnerabilities of women experiencing this transition. Reduced energy intake and inadequate micronutrient intake, combined with estrogen deficiency, heighten the risk for osteoporosis and sarcopenic obesity. Likewise, gastrointestinal adverse events further compromise dietary quality and hydration, while aging physiology amplifies susceptibility to malnutrition. This narrative review synthesizes current evidence on nutritional risks during perimenopause in the context of incretin mimetic pharmacotherapy, highlighting overlapping pathways that influence musculoskeletal health, metabolic resilience, and quality of life. Clinical strategies to mitigate these risks, including protein optimization, micronutrient monitoring, menopausal hormone therapy (osteoporosis/musculoskeletal health), and multidisciplinary care, are discussed alongside research priorities to inform targeted nutrition frameworks. Addressing these gaps is essential to ensure safe, effective, and sustainable obesity management for women in midlife and beyond.
Why this matters
This review [expert-opinion] adds a menopause-specific safety concern to the AOM-as-longevity discussion: reduced intake during treatment may intersect with existing muscle and bone vulnerability. Its proposed nutritional strategies remain clinical guidance rather than demonstrated prevention of sarcopenia or osteoporosis [expert-opinion], and it supplies no new media/community evidence that the longevity trend is spreading.